Huahong花红品牌怎么样 申请店铺

我要投票 Huahong花红在女性洗液行业中的票数:617 更新时间:2026-01-02
Huahong花红是哪个国家的品牌?「Huahong花红」是 广西壮族自治区花红药业股份有限公司 旗下著名品牌。该品牌发源于广西,由创始人韦飞燕在1982期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力Huahong花红品牌出海!将品牌入驻外推网,定制Huahong花红品牌推广信息,可以显著提高Huahong花红产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

Huahong花红怎么样

广西花红药业股份有限公司集药材基地、科研、生产、销售为一体,是国家重点中成药企业,始建于20世纪70年代初。2002年完成国有改制,与上海复星医药(集团)股份有限公司进行合资合作,充分运用复星医药的资金、技术、管理等综合资源,在现代中药、药材种植、医药流通、资本运营等领域实现共赢;2005年花红品牌向健康产业延伸,建立子公司花红俱乐部。

花红药业拥有“花红”驰名保护和40多项国家专利,改制后投入巨资改造现代中药的软硬件设施,通过了GMP、CGMP,达到国际注册标准,是广西区技术中心、国家级高新技术企业。

花红药业GMP生产基地占地200亩、年生产能力达10亿元以上,生产能力规模居广西中成药行业首位。公司拥有以妇科产品为主的中成药50多个品种,包括国家中药保护品种花红片、花红颗粒、葛根芩连丸、消肿止痛酊,以及花红随身洁、养血当归糖浆等。其中独家品种花红片、花红颗粒、花红胶囊、消肿止痛酊、葛根芩连丸、解毒生肌膏入选国家《药品目录(2009年版)》。治疗流感、腹泻的独家产品葛根芩连丸是全国中医院急诊必备用药,由于具有抗病毒、起效快特点,多次在国家发生大的疫情时,被国家卫生部推荐为诊疗用药。主导产品花红片、消肿止痛酊是全国治疗妇科炎症用药和外用镇痛酊剂类用药的知名品牌。

花红药业奉行“关心健康,爱护家庭”的宗旨,秉承“坦诚、开放、严谨、感恩”的企业理念,致力于女性健康事业,为改善和提高女性健康水平,提供专业化的优质药品和服务,发展以品牌为核心的妇科产品群,努力成为中国乃至全球女性用药的一流企业和女性健康专家。

Guangxi Huahong Pharmaceutical Co., Ltd. is a national key Chinese patent medicine enterprise, which integrates the base of medicinal materials, scientific research, production and sales. It was founded in the early 1970s. In 2002, the state-owned restructuring was completed, and a joint venture cooperation was carried out with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to make full use of Fosun Pharmaceutical's capital, technology, management and other comprehensive resources to achieve a win-win situation in the fields of modern Chinese medicine, herbal medicine planting, pharmaceutical circulation, capital operation, etc.; in 2005, Huahong brand extended to the health industry and established a subsidiary Huahong club. Huahong Pharmaceutical Co., Ltd. is well-known for its "Huahong" protection and more than 40 national patents. After the reform, it invested heavily in the reconstruction of the software and hardware facilities of modern Chinese medicine, passed GMP and cGMP, and reached the international registration standard. It is a technology center of Guangxi district and a national high-tech enterprise. Huahong pharmaceutical GMP production base covers an area of 200 mu, with an annual production capacity of more than 1 billion yuan, ranking first in Guangxi's proprietary Chinese medicine industry. The company has more than 50 kinds of traditional Chinese medicine mainly for gynecology products, including Huahong tablet, Huahong granule, Gegen Qinlian pill, Xiaozhong Zhitong tincture, Huahong portable cleaning, blood nourishing Angelica syrup, etc. Among them, the exclusive varieties of Huahong tablet, Huahong granule, Huahong capsule, Xiaozhongzhitong tincture, Gegenqinlian pill and Jiedu Shengji ointment were selected into the National Drug Catalogue (2009 Edition). Gegen Qinlian pill, an exclusive product for the treatment of influenza and diarrhea, is an essential medicine for emergency treatment in Chinese medicine hospitals. Because of its antiviral and quick effect, it has been recommended by the Ministry of health as a medicine for diagnosis and treatment when there are many large epidemics in the country. Huahong tablet and Xiaozhongzhitong tincture, the leading products, are well-known brands for the treatment of gynecological inflammation and external analgesic tincture. Huahong pharmaceutical adheres to the tenet of "caring for health, caring for family", adheres to the enterprise concept of "honesty, openness, preciseness and gratitude", devotes itself to the cause of women's health, provides professional high-quality drugs and services for improving and improving women's health level, develops the gynaecological product group with brand as the core, and strives to become the first-class enterprise and women's medicine in China and even in the world Health experts.

本文链接: https://brand.waitui.com/f7cc93a62.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

印度政府批准电子元件制造计划下的投资金额为4186.3亿卢比

印度政府批准电子元件制造计划下的投资金额为4186.3亿卢比。(财联社)

2小时前

分析师:三星SDI或将持续亏损直至2026年底

NH Investment & Securities以Ju Min-woo为首的分析师表示,三星SDI在2025年第四财季因美国电动汽车需求疲软而录得大于预期的亏损后,可能会持续亏损直至2026年底。这些分析师表示,由于在欧洲的电动汽车电池市场份额不断下滑,这家韩国电池制造商可能比竞争对手受到更大冲击。NH Investment & Securities预计,该公司第四财季将录得3,387亿韩元的营业亏损,而市场平均预期为亏损2,690亿韩元,并预计其2025年年度亏损为1.765万亿韩元。NH Investment & Securities预测,该公司2026年的营业亏损可能收窄至9,670亿韩元。(新浪财经)

2小时前

葡萄牙12月特斯拉新车注册量同比下降12.7%,2025年累计下降22.3%

据葡萄牙汽车协会(ACAP),葡萄牙12月特斯拉新车注册量同比下降12.7%,2025年累计下降22.3%。(财联社)

2小时前

元旦假期首日,全社会跨区域人员流动量超2亿人次

2026年1月1日,全社会跨区域人员流动量20747.5万人次,环比下降0.1%,同比增长20.3%。(央视新闻)

2小时前

挪威2025年新车销量的96%为电动汽车

上周五的官方数据显示,去年在挪威注册的几乎所有新车都是纯电动汽车,其中特斯拉的销量更是一路飙升,使这个北欧国家在逐步淘汰汽油和柴油动力汽车方面巩固了全球领先地位。在税收优惠政策的推动下,2025年注册的所有新车中有95.9%是电动汽车,12月份这一数字接近98%。挪威道路联合会(OFV)的数据显示,这一年度数字高于2024年的88.9%。OFV称,挪威今年登记的新车数量达到创纪录的179549辆,比2024年增长了40%。(新浪财经)

2小时前

本页详细列出关于Huahong花红的品牌信息,含品牌所属公司介绍,Huahong花红所处行业的品牌地位及优势。
咨询